AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04285229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01536015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency: One patch applied every 24 hours~Duration: 10 weeks
Trial: NCT01668667
Drug: GSK1838262 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: GSK1838262 600 mg/day Comparison of 3 doses
Trial: NCT01668667
Drug: GSK1838262 450 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: GSK1838262 450 mg/day Comparison of 3 doses
Trial: NCT01668667
Drug: GSK1838262 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: GSK1838262 300 mg/day Comparison of 3 doses
Trial: NCT01668667
Drug: GSK1838262 Placebo match
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
Trial: NCT02633579
Drug: Erythromycin with atropine
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous administration of erythromycin with saline
Trial: NCT02951364
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg tablet administered orally once daily
Trial: NCT02086799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
Trial: NCT04729140
Drug: Doxycycline Tablets
RxNorm normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Trial: NCT04729140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.
Trial: NCT02787304
Drug: SHP626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
Trial: NCT02787304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01852955
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
Trial: NCT01912976
Drug: Er:YAG AFL-PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
Trial: NCT01912976
Drug: MAL-PDT
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Trial: NCT00648180
Drug: Doxycycline Monohydrate Tablets 100 mg
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT01281969
Drug: Gamunex Intravenous Immunoglobulin
RxNorm normalized name: immunoglobulin G Injection [Gamunex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 gm/kg total, IV (in the vein), over 2 days
Trial: NCT01281969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline, IV (in the vein), over 2 days
Trial: NCT03075410
Drug: GSK3036656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
Trial: NCT03075410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
Trial: NCT00648180
Drug: Adoxa Tablets 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT02763787
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
Trial: NCT04539418
Drug: Vitamin K 2
RxNorm normalized name: vitamin K 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be monitored during the whole protocol.
Trial: NCT02763787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo
Trial: NCT02986828
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
Trial: NCT00347867
Drug: Viagra administration in IUGR/PET pregnancies
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04123873
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg x 4 p.o.
Trial: NCT02644044
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
Trial: NCT01477801
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard guideline based therapy plus placebo
Trial: NCT01198002
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Subcutaneously (SC)
Trial: NCT01198002
Drug: Placebo Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01198002
Drug: Placebo Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01198002
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is a background therapy.
Trial: NCT00048152
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00048152
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g po bid
Trial: NCT02035644
Drug: Jinlida granules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02035644
Drug: placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04123873
Drug: Placebo oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. x 4
Trial: NCT04123873
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV x 1
Trial: NCT02184819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
Trial: NCT01782326
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
Trial: NCT01782326
Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
Trial: NCT02278575
Drug: Atenativ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous transfusion
Trial: NCT00820196
Drug: Nexagon®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00820196
Drug: Nexagon® vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01613560
Drug: AI adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
Trial: NCT01613560
Drug: AI+chemotherapy adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
Trial: NCT02046538
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
Trial: NCT02559817
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00956436
Drug: BIIB022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Q3W
Trial: NCT00950222
Drug: Imipenem/Amikacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will received as empirical therapy for VAP imipenem associated with amikacin.
Trial: NCT00775463
Drug: treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
Trial: NCT00775463
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00589238
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00589238
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03198182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03224351
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEZ/IVA fixed-dose combination tablet for oral administration.
Trial: NCT03224351
Drug: Placebo (matched to VX-659/TEZ/IVA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-659 and TEZ/IVA.
Trial: NCT03979066
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
Trial: NCT02189668
Drug: Antibiotics only (Zosyn then Augmentin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
Trial: NCT01299558
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of GW642444 (55mcg)
Trial: NCT03389893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
Trial: NCT02301715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
Trial: NCT00455286
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02448719
Drug: TAK-792 30 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 30 mg placebo was administered in the morning after a fast.
Trial: NCT02448719
Drug: TAK-792 250 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 250 mg placebo was administered in the morning after a fast.
Trial: NCT02448719
Drug: TAK-792 500 mg placebo
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
Trial: NCT02448719
Drug: TAK-792 750 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 750 mg placebo was administered in the morning after a fast.
Trial: NCT00857506
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 Mega Becquerel (10 mCi)
Trial: NCT02448719
Drug: TAK-792 1250 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 1250 mg placebo was administered in the morning after a fast.
Trial: NCT01851954
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV clarithromycin infusion
Trial: NCT03788083
Drug: Trimix
RxNorm normalized name: Nutrimix Mac Vented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral TriMix injection
Trial: NCT03788083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral placebo injection
Trial: NCT00055601
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
Trial: NCT00475371
Drug: MKC253 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder
Trial: NCT01149356
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01075048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Trial: NCT00989131
Drug: Paclical®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.
Trial: NCT00989131
Drug: Taxol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments.
Trial: NCT04149340
Drug: Cataract surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
Trial: NCT01047943
Drug: Topical application of STA-21 ointment for treatment of psoriasis
RxNorm normalized name: Retinoids for treatment of psoriasis
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00284817
Drug: MEDI-522
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
Trial: NCT00284817
Drug: MEDI-522
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
Trial: NCT00284817
Drug: MEDI-522
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
Trial: NCT00284817
Drug: MEDI-522
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
Trial: NCT00284817
Drug: MEDI-522
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
Trial: NCT03818685
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radiotherapy will be maintained in each Arm.
Trial: NCT00725582
Drug: IMA-026
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04103060
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel applied topically twice daily for 6 weeks
Trial: NCT04172987
Drug: EE/NGM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oral contraceptive administered orally
Trial: NCT01477281
Drug: Daflon
RxNorm normalized name: Daflonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
Trial: NCT01477281
Drug: Venaflon (Diosmin and Hesperidin)
RxNorm normalized name: Veraflox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
Trial: NCT02943486
Drug: Fitostimoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triticum vulgare
Trial: NCT01201317
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablet
Trial: NCT01201317
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tablet
Trial: NCT01201317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00852540
Drug: Retpamulin Ointment, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
Trial: NCT03781323
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours.
Trial: NCT00735709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching capsules
Trial: NCT00789321
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 5 mg tablets placebo to amlodipine daily for 6 weeks
Trial: NCT02280434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00801944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02068209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive a placebo 1 hour before outpatient hysteroscopy
Trial: NCT03775070
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition.
Trial: NCT01717690
Drug: CHG antiseptic body cleanser
RxNorm normalized name: CHG Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
Trial: NCT00842270
Drug: AB1010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/day
Trial: NCT00842270
Drug: AB1010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,5 mg/kg/day
Trial: NCT00842270
Drug: AB1010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg/day
Trial: NCT00842270
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to AB1010 dosages
Trial: NCT01433159
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
Trial: NCT00084240
Drug: Azithromycin/Chloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00257790
Drug: Tobramycin once a day
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03659344
Drug: Vicryl plus
RxNorm normalized name: VICRYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using vicryl sutures which coated with triclosan (antibiotic)
Trial: NCT00079976
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00266708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate Placebo 35 mg weekly
Trial: NCT04882371
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Chemotherapy for Breast Cancer